Overview

Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases

Status:
Completed

Trial end date:
2018-10-10

Target enrollment:

Participant gender:

Summary

To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases; To determine the safety of HS-25 (20mg) combination with Atorvastatin in subjects with hypercholesterolemia and coronary heart diseases

Phase:

Phase 3

Details

Lead Sponsor:

Zhejiang Hisun Pharmaceutical Co. Ltd.

Treatments:

Atorvastatin
Atorvastatin Calcium